PTPRC and neoplasm: The mice treated with anti-PD-L1 alone did not demonstrate a significant elevation of leukocyte (CD45+) infiltration into the tumor relative to the control, whereas a significant increase was observed in the group receiving TTFields with concomitant anti-PD-L1 (Figure 3C).